Skip to main content
SpringerLink
Log in

Tinkering with Nature: The Tale of Optimizing Peptide Based Cancer Vaccines

  • Chapter
Tumor Immunology and Cancer Vaccines

Part of the book series: Cancer Treatment and Research ((CTAR,volume 123))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Townsend, A., and H. Bodmer. 1989. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol 7:601.

    PubMed  CAS  Google Scholar 

  2. Davis, M.M., M. Krogsgaard, J.B. Huppa, C. Sumen, M.A. Purbhoo, D.J. Irvine, L.C. Wu, and L. Ehrlich. 2003. Dynamics of cell surface molecules during T cell recognition. Annu Rev Biochem 72:717.

    Article  PubMed  CAS  Google Scholar 

  3. Renkvist, N., C. Castelli, P.F. Robbins, and G. Parmiani. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3.

    Article  PubMed  CAS  Google Scholar 

  4. Van Pel, A., P. van der Bruggen, P.G. Coulie, V.G. Brichard, B. Lethe, B. van den Eynde, C. Uyttenhove, J.C. Renauld, and T. Boon. 1995. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229.

    Article  PubMed  Google Scholar 

  5. Wang, R.F. 1999. Human tumor antigens: implications for cancer vaccine development. J Mol Med 77:640.

    Article  PubMed  CAS  Google Scholar 

  6. Hanada, K., J.W. Yewdell, and J.C. Yang. 2004. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427:252.

    Article  PubMed  CAS  Google Scholar 

  7. Irvine, D. J., M.A. Purbhoo, M. Krogsgaard, and M.M. Davis. 2002. Direct observation of ligand recognition by T cells. Nature 419:845.

    Article  PubMed  CAS  Google Scholar 

  8. Palmer, E. 2003. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol 3:383.

    Article  PubMed  CAS  Google Scholar 

  9. Starr, T.K., S.C. Jameson, and K.A. Hogquist. 2003. Positive and negative selection of T cells. Annu Rev Immunol 21:139.

    Article  PubMed  CAS  Google Scholar 

  10. Peterson, D.A., R.J. DiPaolo, O. Kanagawa, and E.R. Unanue. 1999. Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity 11:453.

    Article  PubMed  CAS  Google Scholar 

  11. Bouneaud, C., P. Kourilsky, and P. Bousso. 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13:829.

    Article  PubMed  CAS  Google Scholar 

  12. Sandberg, J.K., L. Franksson, J. Sundback, J. Michaelsson, M. Petersson, A. Achour, R.P. Wallin, N.E. Sherman, T. Bergman, H. Jornvall, D.F. Hunt, R. Kiessling, and K. Karre. 2000. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol 165:25.

    PubMed  CAS  Google Scholar 

  13. Yan, J., and M.J. Mamula. 2002. Autoreactive T cells revealed in the normal repertoire: escape from negative selection and peripheral tolerance. J Immunol 168:3188.

    PubMed  CAS  Google Scholar 

  14. Muller, V., and S. Bonhoeffer. 2003. Quantitative constraints on the scope of negative selection. Trends Immunol 24:132.

    Article  PubMed  CAS  Google Scholar 

  15. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L.A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 185:833.

    Article  PubMed  CAS  Google Scholar 

  16. de Visser, K.E., T.A. Cordaro, D. Kioussis, J.B. Haanen, T.N. Schumacher, and A.M. Kruisbeek. 2000. Tracing and characterization of the low-avidity self-specific T cell repertoire. Eur J Immunol 30:1458.

    Article  PubMed  Google Scholar 

  17. Colella, T.A., T.N. Bullock, L.B. Russell, D.W. Mullins, W.W. Overwijk, C.J. Luckey, R.A. Pierce, N.P. Restifo, and V.H. Engelhard. 2000. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 191:1221.

    Article  PubMed  CAS  Google Scholar 

  18. Cordaro, T.A., K.E. de Visser, F.H. Tirion, T.N. Schumacher, and A.M. Kruisbeek. 2002. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol 168:651.

    PubMed  CAS  Google Scholar 

  19. Dyall, R., W.B. Bowne, L.W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J.J. Lewis, A.N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J Exp Med 188:1553.

    Article  PubMed  CAS  Google Scholar 

  20. Men, Y., I. Miconnet, D. Valmori, D. Rimoldi, J.C. Cerottini, and P. Romero. 1999. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J Immunol 162:3566.

    PubMed  CAS  Google Scholar 

  21. El-Shami, K.M., B. Tirosh, D. Popovic, L. Carmon, E. Tzehoval, E. Vadai, M. Feldman, and L. Eisenbach. 2000. Induction of antitumor immunity by proteasome-inhibited syngeneic fibroblasts pulsed with a modified TAA peptide. Int J Cancer 85:236.

    PubMed  CAS  Google Scholar 

  22. Mullins, D.W., T.N. Bullock, T.A. Colella, V.V. Robila, and V.H. Engelhard. 2001. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. J Immunol 167:4853.

    PubMed  CAS  Google Scholar 

  23. Overwijk, W.W., M.R. Theoret, S.E. Finkelstein, D.R. Surman, L.A. de Jong, F.A. Vyth-Dreese, T.A. Dellemijn, P.A. Antony, P.J. Spiess, D.C. Palmer, D.M. Heimann, C.A. Klebanoff, Z. Yu, L.N. Hwang, L. Feigenbaum, A.M. Kruisbeek, S.A. Rosenberg, and N.P. Restifo. 2003. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569.

    Article  PubMed  CAS  Google Scholar 

  24. Falk, K., O. Rotzschke, S. Stevanovic, G. Jung, and H.G. Rammensee. 1991. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290.

    Article  PubMed  CAS  Google Scholar 

  25. Maier, R., K. Falk, O. Rotzschke, B. Maier, V. Gnau, S. Stevanovic, G. Jung, H.G. Rammensee, and A. Meyerhans. 1994. Peptide motifs of HLA-A3,-A24, and-B7 molecules as determined by pool sequencing. Immunogenetics 40:306.

    Article  PubMed  CAS  Google Scholar 

  26. Okugawa, T., Y. Ikuta, Y. Takahashi, H. Obata, K. Tanida, M. Watanabe, S. Imai, R. Furugen, Y. Nagata, N. Toyoda, and H. Shiku. 2000. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol 30:3338.

    Article  PubMed  CAS  Google Scholar 

  27. Romero, P., G. Corradin, I.F. Luescher, and J.L. Maryanski. 1991. H-2Kd-restricted antigenic peptides share a simple binding motif. J Exp Med 174:603.

    Article  PubMed  CAS  Google Scholar 

  28. Brusic, V., G. Rudy, and L.C. Harrison. 1997. MHCPEP, a database of MHC-binding peptides: update 1997. Nucleic Acids Res 26:368.

    Article  Google Scholar 

  29. Ruppert, J., J. Sidney, E. Celis, R.T. Kubo, H.M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.

    Article  PubMed  CAS  Google Scholar 

  30. Aarnoudse, C.A., P.B. van den Doel, B. Heemskerk, and P.I. Schrier. 1999. Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 82:442.

    Article  PubMed  CAS  Google Scholar 

  31. Speir, J.A., J. Stevens, E. Joly, G.W. Butcher, and I.A. Wilson. 2001. Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity 14:81.

    Article  PubMed  CAS  Google Scholar 

  32. Parker, K.C., M.A. Bednarek, and J.E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163.

    PubMed  CAS  Google Scholar 

  33. Gulukota, K., J. Sidney, A. Sette, and C. DeLisi. 1997. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J Mol Biol 267:1258.

    Article  PubMed  CAS  Google Scholar 

  34. Rammensee, H., B.J., N.P. Emmerich, O.A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213.

    Article  PubMed  CAS  Google Scholar 

  35. Donnes, P., and A. Elofsson. 2002. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 3:25.

    Article  PubMed  Google Scholar 

  36. Flower, D.R. 2003. Towards in silico prediction of immunogenic epitopes. Trends Immunol 24:667.

    Article  PubMed  CAS  Google Scholar 

  37. Celis, E., V. Tsai, C. Crimi, R. DeMars, P.A. Wentworth, R.W. Chesnut, H.M. Grey, A. Sette, and H.M. Serra. 1994. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A 91:2105.

    Article  PubMed  CAS  Google Scholar 

  38. Matsumura, M., D.H. Fremont, P.A. Peterson, and I.A. Wilson. 1992. Emerging principles for the recognition of peptide antigens by MHC class I molecules. Science 257:927.

    Article  PubMed  CAS  Google Scholar 

  39. Madden, D.R., D.N. Garboczi, and D.C. Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 75:693.

    Article  PubMed  CAS  Google Scholar 

  40. Batalia, M.A., and E.J. Collins. 1997. Peptide binding by class I and class II MHC molecules. Biopolymers 43:281.

    Article  PubMed  CAS  Google Scholar 

  41. Bjorkman, P.J., M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506.

    Article  PubMed  CAS  Google Scholar 

  42. Hillig, R.C., P.G. Coulie, V. Stroobant, W. Saenger, A. Ziegler, and M. Hulsmeyer. 2001. Highresolution structure of HLA-A*0201 in complex with a tumour-specific antigenic peptide encoded by the MAGE-A4 gene. J Mol Biol 310:1167.

    Article  PubMed  CAS  Google Scholar 

  43. Kuhns, J.J., M.A. Batalia, S. Yan, and E.J. Collins. 1999. Poor binding of a HER-2/neu epitope (GP2) to HLA-A2.1 is due to a lack of interactions with the center of the peptide. J Biol Chem 274:36422–7:36422.

    Article  PubMed  CAS  Google Scholar 

  44. Sliz, P., O. Michielin, J.C. Cerottini, I. Luescher, P. Romero, M. Karplus, and D.C. Wiley. 2001. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J Immunol 167:3276.

    PubMed  CAS  Google Scholar 

  45. Bouvier, M., and D.C. Wiley. 1994. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 265:398.

    Article  PubMed  CAS  Google Scholar 

  46. Kersh, G.J., and P.M. Allen. 1996. Structural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligands. J Exp Med 184:1259.

    Article  PubMed  CAS  Google Scholar 

  47. Sloan-Lancaster, J., and P.M. Allen. 1996. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 14:1.

    Article  PubMed  CAS  Google Scholar 

  48. Ding, Y.H., B.M. Baker, D.N. Garboczi, W.E. Biddison, and D.C. Wiley. 1999. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. Immunity 11:45.

    Article  PubMed  CAS  Google Scholar 

  49. Degano, M., K.C. Garcia, V. Apostolopoulos, M.G. Rudolph, L. Teyton, and I.A. Wilson. 2000. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. Immunity 12:251.

    Article  PubMed  CAS  Google Scholar 

  50. Baker, B.M., S.J. Gagnon, W.E. Biddison, and D.C. Wiley. 2000. Conversion of a T cell antagonist into an agonist by repairing a defect in the TCR/peptide/MHC interface: implications for TCR signaling. Immunity 13:475.

    Article  PubMed  CAS  Google Scholar 

  51. Slansky, J.E., F.M. Rattis, L.F. Boyd, T. Fahmy, E.M. Jaffee, J.P. Schneck, D.H. Margulies, and D.M. Pardoll. 2000. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 13:529.

    Article  PubMed  CAS  Google Scholar 

  52. Zaremba, S., E. Barzaga, M. Zhu, N. Soares, K.Y. Tsang, and J. Schlom. 1997. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570.

    PubMed  CAS  Google Scholar 

  53. Salazar, E., S. Zaremba, P.M. Arlen, K.Y. Tsang, and J. Schlom. 2000. Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide. Int J Cancer 85:829.

    Article  PubMed  CAS  Google Scholar 

  54. Fong, L., Y. Hou, A. Rivas, C. Benike, A. Yuen, G.A. Fisher, M.M. Davis, and E.G. Engleman. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 98:8809.

    Article  PubMed  CAS  Google Scholar 

  55. Dutoit, V., V. Rubio-Godoy, M.J. Pittet, A. Zippelius, P.Y. Dietrich, F.A. Legal, P. Guillaume, P. Romero, J.C. Cerottini, R.A. Houghten, C. Pinilla, and D. Valmori. 2002. Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med 196:207.

    Article  PubMed  CAS  Google Scholar 

  56. Castilleja, A., D. Carter, C.L. Efferson, N.E. Ward, K. Kawano, B. Fisk, A.P. Kudelka, D.M. Gershenson, J.L. Murray, C.A. O’Brian, and C.G. Ioannides. 2002. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/neu protooncogene (369–377) selected by molecular modeling of the peptide: HLA-A2 complex. J Immunol 169:3545.

    PubMed  CAS  Google Scholar 

  57. Carrabba, M.G., C. Castelli, M.J. Maeurer, P. Squarcina, A. Cova, L. Pilla, N. Renkvist, G. Parmiani, and L. Rivoltini. 2003. Suboptimal activation of CD8(+) T cells by melanoma-derived altered peptide ligands: role of Melan-A/MART-1 optimized analogues. Cancer Res 63:1560.

    PubMed  CAS  Google Scholar 

  58. Tangri, S., G.Y. Ishioka, X. Huang, J. Sidney, S. Southwood, J. Fikes, and A. Sette. 2001. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 194:833.

    Article  PubMed  CAS  Google Scholar 

  59. Hemmer, B., M. Vergelli, C. Pinilla, R. Houghten, and R. Martin. 1998. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today 19:163.

    Article  PubMed  CAS  Google Scholar 

  60. de Koster, H.S., C.J. Vermeulen, H.S. Hiemstra, R. Amons, J.W. Drijfhout, and F. Koning. 1999. Definition of agonists and design of antagonists for alloreactive T cell clones using synthetic peptide libraries. Int Immunol 11:585.

    Article  PubMed  Google Scholar 

  61. Borras, E., R. Martin, V. Judkowski, J. Shukaliak, Y. Zhao, V. Rubio-Godoy, D. Valmori, D. Wilson, R. Simon, R. Houghten, and C. Pinilla. 2002. Findings on T cell specificity revealed by synthetic combinatorial libraries. J Immunol Methods 267:79.

    Article  PubMed  CAS  Google Scholar 

  62. Valmori, D., J.F. Fonteneau, C.M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J.C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750.

    PubMed  CAS  Google Scholar 

  63. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A. Steinle, T. Wolfel, D. Lienard, V. Brichard, A. van Pel, F. Jotereau, and J.C. Cerottini. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J Immunol 159:2366.

    PubMed  CAS  Google Scholar 

  64. Schneider, J., V. Brichard, T. Boon, K.H. Meyer zum Buschenfelde, and T. Wolfel. 1998. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 75:451.

    Article  PubMed  CAS  Google Scholar 

  65. Dutoit, V., R.N. Taub, K.P. Papadopoulos, S. Talbot, M.L. Keohan, M. Brehm, S. Gnjatic, P.E. Harris, B. Bisikirska, P. Guillaume, J.C. Cerottini, C.S. Hesdorffer, L.J. Old, and D. Valmori. 2002. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest 110:1813.

    Article  PubMed  CAS  Google Scholar 

  66. Sharma, A.K., J.J. Kuhns, S. Yan, R.H. Friedline, B. Long, R. Tisch, and E.J. Collins. 2001. Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts. J Biol Chem 276:21443.

    Article  PubMed  CAS  Google Scholar 

  67. Saito, N.G., H.C. Chang, and Y. Paterson. 1999. Recognition of an MHC class I-restricted antigenic peptide can be modulated by para-substitution of its buried tyrosine residues in a TCR-specific manner. J Immunol 162:5998.

    PubMed  CAS  Google Scholar 

  68. Pogue, R.R., J. Eron, J.A. Frelinger, and M. Matsui. 1995. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc Natl Acad Sci U S A 92:8166.

    Article  PubMed  CAS  Google Scholar 

  69. Tourdot, S., A. Scardino, E. Saloustrou, D.A. Gross, S. Pascolo, P. Cordopatis, F.A. Lemonnier, and K. Kosmatopoulos. 2000. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol 30:3411.

    Article  PubMed  CAS  Google Scholar 

  70. Scardino, A.,D.A. Gross, P. Alves, J.L. Schultze, S. Graff-Dubois, O. Faure, S. Tourdot, S. Chouaib, L.M. Nadler, F.A. Lemonnier, R.H. Vonderheide, A.A. Cardoso, and K. Kosmatopoulos. 2002. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 168:5900.

    PubMed  Google Scholar 

  71. Michielin, O., and M. Karplus. 2002. Binding free energy differences in a TCR-peptide-MHC complex induced by a peptide mutation: a simulation analysis. J Mol Biol 324:547.

    Article  PubMed  CAS  Google Scholar 

  72. Parkhurst, M.R., M.L. Salgaller, S. Southwood, P.F. Robbins, A. Sette, S.A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A?0201-binding residues. J Immunol 157:2539.

    PubMed  CAS  Google Scholar 

  73. Salgaller, M.L., F.M. Marincola, J.N. Cormier, and S.A. Rosenberg. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749.

    PubMed  CAS  Google Scholar 

  74. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, and D.E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321.

    Article  PubMed  CAS  Google Scholar 

  75. Smith, J.W. I., E.B. Walker, B.A. Fox, D. Haley, K.P. Wisner, T. Doran, B. Fisher, L. Justice, W. Wood, J. Vetto, H. Maecker, A. Dols, S. Meijer, H.-M. Hu, P. Romero, W.G. Alvord, and W.J. Urba. 2003. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol 21:1562.

    Article  PubMed  CAS  Google Scholar 

  76. Cox, A.L., J. Skipper, Y. Chen, R.A. Henderson, T.L. Darrow, J. Shabanowitz, V.H. Engelhard, D.F. Hunt, and C.L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.

    Article  PubMed  CAS  Google Scholar 

  77. Zarour, H., C. De Smet, F. Lehmann, M. Marchand, B. Lethe, P. Romero, T. Boon, and J.C. Renauld. 1996. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. J Invest Dermatol 107:63.

    Article  PubMed  CAS  Google Scholar 

  78. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, S.L. Topalian, R.M. Sherry, N.P. Restifo, J.R. Wunderlich, C.A. Seipp, L. Rogers-Freezer, K.E. Morton, S.A. Mavroukakis, L. Gritz, D.L. Panicali, and D.E. White. 2003. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 9:2973.

    PubMed  CAS  Google Scholar 

  79. Ayyoub, M., A. Zippelius, M.J. Pittet, D. Rimoldi, D. Valmori, J.C. Cerottini, P. Romero, F. Lejeune, D. Lienard, and D.E. Speiser. 2003. Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells. Clin Cancer Res 9:669.

    PubMed  CAS  Google Scholar 

  80. Phan, G.Q., C.E. Touloukian, J.C. Yang, N.P. Restifo, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, C.A. Seipp, L.J. Freezer, K.E. Morton, S.A. Mavroukakis, D.E. White, and S.A. Rosenberg. 2003. Immunization of patients with metastatic melanoma using both class I-and class II-restricted peptides from melanoma-associated antigens. J Immunother 26:349.

    Article  PubMed  CAS  Google Scholar 

  81. Lienard, D., D. Rimoldi, M. Marchand, P.Y. Dietrich, N. van Baren, C. Geldhof, P. Batard, P. Guillaume, M. Ayyoub, M.J. Pittet, A. Zippelius, K. Fleischhauer, F. Lejeune, J.C. Cerottini, P. Romero, and D.E. Speiser. 2004. Sustained ex vivo detectable activation of Melan-A specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 4:4.

    PubMed  Google Scholar 

  82. Falo, L.D. J., L.J. Colarusso, B. Benacerraf, and K.L. Rock. 1992. Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc Natl Acad Sci U S A 89:8347.

    Article  PubMed  CAS  Google Scholar 

  83. Powell, M.F., H. Grey, F. Gaeta, A. Sette, and S. Colon. 1992. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J Pharm Sci 81:731.

    Article  PubMed  CAS  Google Scholar 

  84. Kozlowski, S., M. Corr, T. Takeshita, L.F. Boyd, C.D. Pendleton, R.N. Germain, J.A. Berzofsky, and D.H. Margulies. 1992. Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med 175:1417.

    Article  PubMed  CAS  Google Scholar 

  85. Sherman, L.A., T.A. Burke, and J.A. Biggs. 1992. Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med 175:1221.

    Article  PubMed  CAS  Google Scholar 

  86. Widmann, C., J.L. Maryanski, P. Romero, and G. Corradin. 1991. Differential stability of antigenic MHC class I-restricted synthetic peptides. J Immunol 147:3745.

    PubMed  CAS  Google Scholar 

  87. Zinkernagel, R.M., S. Ehl, P. Aichele, S. Oehen, T. Kundig, and H. Hengartner. 1997. Antigen localisation regulates immune responses in a dose-and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 156:199.

    Article  PubMed  CAS  Google Scholar 

  88. Ayyoub, M., H. Mazarguil, B. Monsarrat, B. Van den Eynde, and J.E. Gairin. 1999. A structure-based approach to designing non-natural peptides that can activate anti-melanoma cytotoxic T cells. J Biol Chem 274:10227.

    Article  PubMed  CAS  Google Scholar 

  89. Brinckerhoff, L.H., V.V. Kalashnikov, L.W. Thompson, G.V. Yamshchikov, R.A. Pierce, H.S. Galavotti, V.H. Engelhard, and C.L. Slingluff, Jr. 1999. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27–35) peptide: implications for peptide vaccines. Int J Cancer 83:326.

    Article  PubMed  CAS  Google Scholar 

  90. Stemmer, C., A. Quesnel, A. Prevost-Blondel, C. Zimmermann, S. Muller, J.P. Briand, and H. Pircher. 1999. Protection against lymphocytic choriomeningitis virus infection induced by a reduced peptide bond analogue of the H-2Db-restricted CD8(+) T cell epitope GP33. J Biol Chem 274:5550.

    Article  PubMed  CAS  Google Scholar 

  91. Maillere, B., G. Mourier, M. Herve, and A. Menez. 1995. Fine chemical modifications at N-and C-termini enhance peptide presentation to T cells by increasing the lifespan of both free and MHC-complexed peptides. Mol Immunol 32:1377.

    Article  PubMed  CAS  Google Scholar 

  92. Guichard, G., N. Benkirane, G. Zeder-Lutz, M.H. van Regenmortel, J.P. Briand, and S. Muller. 1994. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proc Natl Acad Sci U S A 91:9765.

    Article  PubMed  CAS  Google Scholar 

  93. Guichard, G., F. Connan, R. Graff, M. Ostankovitch, S. Muller, J.G. Guillet, J. Choppin, and J.P. Briand. 1996. Partially modified retro-inverso pseudopeptides as non-natural ligands for the human class I histocompatibility molecule HLA-A2. J Med Chem 39:2030.

    Article  PubMed  CAS  Google Scholar 

  94. Blanchet, J.S., D. Valmori, I. Dufau, M. Ayyoub, C. Nguyen, P. Guillaume, B. Monsarrat, J.C. Cerottini, P. Romero, and J.E. Gairin. 2001. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular antimelanoma immunotherapy. J Immunol 167:5852.

    PubMed  CAS  Google Scholar 

  95. Quesnel, A., A. Zerbib, F. Connan, J.G. Guillet, J.P. Briand, and J. Choppin. 2001. Synthesis and antigenic properties of reduced peptide bond analogues of an immunodominant epitope of the melanoma MART-1 protein. J Pept Sci 7:157.

    Article  PubMed  CAS  Google Scholar 

  96. Guichard, G., A. Zerbib, F.A. Le Gal, J. Hoebeke, F. Connan, J. Choppin, J.P. Briand, and J.G. Guillet. 2000. Melanoma peptide MART-1(27–35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes. J Med Chem 43:3803.

    Article  PubMed  CAS  Google Scholar 

  97. Ayyoub, M., B. Monsarrat, H. Mazarguil, and J.E. Gairin. 1998. Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogs. Rapid Commun Mass Spectrom 12:557.

    Article  PubMed  CAS  Google Scholar 

  98. Hooper, N.M. 1991. Angiotensin converting enzyme: implications from molecular biology for its physiological functions. Int J Biochem 23:641.

    Article  PubMed  CAS  Google Scholar 

  99. Araujo, M.C., R.L. Melo, M.H. Cesari, M.A. Juliano, L. Juliano, and A. K. Carmona. 2000. Peptidase specificity characterization of C-and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 39:8519.

    Article  PubMed  CAS  Google Scholar 

  100. Ostankovitch, M., G. Guichard, F. Connan, S. Muller, A. Chaboissier, J. Hoebeke, J. Choppin, J.P. Briand, and J.G. Guillet. 1998. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J Immunol 161:200.

    PubMed  CAS  Google Scholar 

  101. Calbo, S., G. Guichard, P. Bousso, S. Muller, P. Kourilsky, J.P. Briand, and J.P. Abastado. 1999. Role of peptide backbone in T cell recognition. J Immunol 162:4657.

    PubMed  CAS  Google Scholar 

  102. Bianco, A., C. Zabel, P. Walden, and G. Jung. 1998. N-Hydroxy-amide analogues of MHC-class I peptide ligands with nanomolar binding affinities. J Pept Sci 4:471.

    Article  PubMed  CAS  Google Scholar 

  103. Hin, S., C. Zabel, A. Bianco, G. Jung, and P. Walden. 1999. Cutting edge: N-hydroxy peptides: a new class of TCR antagonists. J Immunol 163:2363.

    PubMed  CAS  Google Scholar 

  104. Calbo, S., G. Guichard, S. Muller, P. Kourilsky, J.P. Briand, and J. P. Abastado. 2000. Antitumor vaccination using a major histocompatibility complex (MHC) class I-restricted pseudopeptide with reduced peptide bond. J Immunother 23:125.

    Article  PubMed  CAS  Google Scholar 

  105. den Boer, A.T., L. Diehl, G.J. van Mierlo, E.I. van der Voort, M.F. Fransen, P. Krimpenfort, C.J. Melief, R. Offringa, and R.E. Toes. 2001. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J Immunol 167:2522.

    Google Scholar 

  106. Bakker, A.B., S.H. van der Burg, R.J. Huijbens, J.W. Drijfhout, C.J. Melief, G.J. Adema, and C.G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit antimelanoma CTL recognizing the wild-type epitope. Int J Cancer 70:302.

    Article  PubMed  CAS  Google Scholar 

  107. Rivoltini, L., P. Squarcina, D.J. Loftus, C. Castelli, P. Tarsini, A. Mazzocchi, F. Rini, V. Viggiano, F. Belli, and G. Parmiani. 1999. A superagonist variant of peptide MART1/Melan A27–35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res 59:301.

    PubMed  CAS  Google Scholar 

  108. Chen, J.L., P.R. Dunbar, U. Gileadi, E. Jager, S. Gnjatic, Y. Nagata, E. Stockert, D.L. Panicali, Y.T. Chen, A. Knuth, L.J. Old, and V. Cerundolo. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 165:948.

    PubMed  CAS  Google Scholar 

  109. Romero, P., V. Dutoit, V. Rubio-Godoy, D. Lienard, D. Speiser, P. Guillaume, K. Servis, D. Rimoldi, J.C. Cerottini, and D. Valmori. 2001. CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res 7:766s.

    PubMed  CAS  Google Scholar 

  110. Petersen, T.R., S. Buus, S. Brunak, M.H. Nissen, L.A. Sherman, and M.H. Claesson. 2001. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 53:357.

    Article  PubMed  CAS  Google Scholar 

  111. Graff-Dubois, S., O. Faure, D.A. Gross, P. Alves, A. Scardino, S. Chouaib, F.A. Lemonnier, and K. Kosmatopoulos. 2002. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1,-A2,-A3,-A4,-A6,-A10, and-A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169:575.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Office of Information Technology, Ludwig Institute for Cancer Research, Epalinges, Switzerland

    Olivier Michielin & Theres Fagerberg

  2. Multidisciplinary Oncology Center, University Hospital (CHUV), Lausanne, Switzerland

    Olivier Michielin

  3. Translational Medicine and Technology, GlaxoSmithKline R&D, Ware, UK

    Jean-Sebastien Blanchets

  4. College of Physician and Surgeons, Columbia University, New York, USA

    Danila Valmori & Maha Ayyoub

  5. Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research, Lausanne, Switzerland

    Danila Valmori, Verena Rubio-Godoy, Daniel Speiser, Pedro Alves & Pedro Romero

  6. Ludwig Institute for Cancer Research, Lausanne branch, Epalinges, Switzerland

    Immanuel Luescher, Jean-Charles Cerottini & Pedro Romero

  7. Institut de Pharmacologie et Biologie Structurale, UMR 5080, CNRS, Toulouse, France

    Jean-Edouard Gairin

Authors
  1. Olivier Michielin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Sebastien Blanchets
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Theres Fagerberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Danila Valmori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Verena Rubio-Godoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Daniel Speiser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Maha Ayyoub
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pedro Alves
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Immanuel Luescher
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jean-Edouard Gairin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jean-Charles Cerottini
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Pedro Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Vaccine Branch, National Cancer Institute, Bethesda Naval Hospital Bethesda, MD, USA

    Samir N. Khleif

  2. King Hussein Cancer Center, Amman, Jordan

    Samir N. Khleif

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Kluwer Academic Publishers

About this chapter

Cite this chapter

Michielin, O. et al. (2005). Tinkering with Nature: The Tale of Optimizing Peptide Based Cancer Vaccines. In: Khleif, S.N. (eds) Tumor Immunology and Cancer Vaccines. Cancer Treatment and Research, vol 123. Springer, Boston, MA. https://doi.org/10.1007/0-387-27545-2_12

Download citation

  • DOI: https://doi.org/10.1007/0-387-27545-2_12

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-8119-4

  • Online ISBN: 978-0-387-27545-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation